CD19 and lymphoma: However, in the long term, we envision that our CD19/BCMA-targeted dual-CAR NK-92 can be used as an off-the-shelf therapeutic for B-cell leukemia, lymphoma and myeloma patients to address the current problems of antigen-negative and antigen-positive relapses after autologous single CAR-T administration.